A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Sarepta Therapeutics, Inc. SRPT
Mixed broader-coverage candidate · Sarepta Therapeutics, Inc.
On FrontierLab's discovery record since 2026-07-09 (6 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-18), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | -20.4% |
|---|---|
| Gross margin | 58.6% |
| Gross profits / assets | 0.36 |
| Rule of 40 | -27.7 |
| Net margin | -7.3% |
| Cash runway (months) | 103.2 |
| PEG | — |
| Price / sales | 1 |
Quality checklist
- ✗ Revenue growth — -20.4% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.36 (pass ≥ 0.33)
- ~ Gross margin — 58.6% (pass ≥ 60%)
- ~ Cash generation
- ✓ Share dilution — -1.1%
Fundamentals — snapshot as of 2026-08-18
| Stage | Established |
|---|---|
| Share issuance (YoY) | -1.1% · flat share count |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-2.90 |
| Burn multiple | 0 |
| Gross-margin trend (pts) | -20.7 |
| Cash / assets | 0.25 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-05 |
Momentum context — a snapshot from 2026-08-18, not current
| Price at surface | $18.18 (as of 2026-08-18) |
|---|---|
| 52-week range | $14.68 – $25.32 |
| % off 52-wk high | -28.2% |
| RSI (14) | 60 |
| Relative volume | 0.5× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-18 (end-of-day). How grades are computed →